Background: There are controversies about the adequacy of tumor tissue sample on which the sequencing of molecular diagnosiscould be performed to achieve the targeted-therapy on lung cancer. The aim of this study is to demonstrate the role of the LaserMicrodissection Pressure Catapulting (LMPC) technique to obtain adequate tumor tissue sample for the molecular analysis of genemutations in the target therapy of lung cancer.Findings: From a consecutive series of 24 patients with a diagnosis of locally-advanced or metastatic Non Small Cell LungCancer (NSCLC), we performed 29 diagnostic procedures using the system of LMPC, to obtain an homogeneous samples where itwas possible to run the sequencing of the 4 most frequently mutated exons of Epidermal Growth Factor Receptor (EGFR) (exon 18,19, 20, 21).Results: There were 14 males (58.3%) and 10 females (41.7%), with a mean age of 61 years old. Twenty one patients wereaffected by adenocarcinomas, 2 by squamous cell carcinomas and 1 by large cell carcinoma. We were able to obtain the sequencingon 26 out 29 samples (89,6%) for EGFR mutation. EGFR mutation rate in our population was 7,7%. In 5 samples, we found a polymorphismin exon 20 and one of them carried a mutation on exon 18 as well. In another sample we found the deletion of exon 19. Onthe other 20 samples we did not find any mutation.Conclusions: Our preliminary data suggest that the LMPC technique permits to obtain the tumor cells sample more homogeneousfacilitating the application of biological molecular analysis for EGFR-gene mutation in a larger number of patients withNSCLC.
|Numero di pagine||4|
|Rivista||Acta Medica Mediterranea|
|Stato di pubblicazione||Published - 2014|
All Science Journal Classification (ASJC) codes